TROG 94.01/AGITG IG9401 - Oesophagus - Localised Resectable (IG9401)

By w.paterson
15 August, 2021
0 Comments

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australasian Gastro-Intestinal Cancer Trials Group (AGITG)

24 June, 2025

TROG 2024 Annual Research Report highlights a year of achievements

LATEST NEWS: 24 JUNE 2025 The latest annual report

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

TROG 95.01 – Rectal Cancer

TROG 92.01 – PCNSL (Phase II)

Related Post

TROG 2024 Annual Research Report highlights a year of achievements

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer